Skip to main content
Fredun Pharmaceuticals Limited logo

Fredun Pharmaceuticals Limited — Investor Relations & Filings

Ticker · 539730 ISIN · INE194R01017 LEI · 984500A2DC584976AC60 BSE.NS Manufacturing
Open in API
Filings indexed 536 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country IN India
Listing BSE.NS 539730

About Fredun Pharmaceuticals Limited

http://www.fredungroup.com/

Fredun Pharmaceuticals Limited specializes in the development, manufacturing, and marketing of a broad range of healthcare formulations. The product portfolio includes diverse dosage forms such as tablets, capsules, ointments, and liquid orals, covering therapeutic areas including cardiology, diabetology, anti-infectives, and gastroenterology. The company also operates specialized divisions for nutraceuticals and veterinary products. With a focus on quality and affordability, the organization maintains manufacturing facilities compliant with WHO-GMP standards. Its operations extend across various international markets, supported by a robust export strategy and a commitment to meeting global regulatory requirements. The company emphasizes research-driven production to address evolving medical needs through a comprehensive suite of healthcare solutions.

Recent filings

Filing Released Lang Actions
Newspaper clipping Information regarding 39th Annual General Meeting to be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM).
Regulatory Filings Classification · 86% confidence The document is a submission to the stock exchange enclosing newspaper clippings about the company’s upcoming 39th Annual General Meeting (notice date, time, and medium) filed to comply with SEBI Listing Regulations. It does not contain the AGM materials themselves (AGM-R), nor is it a proxy statement (PSI) or a report publication (RPA). It is a general regulatory announcement/compliance filing, fitting the Regulatory Filings (RNS) category.
2026-06-01 English
Annual Secretarial Compliance Report for the year ended 31st March, 2026.
Regulatory Filings Classification · 85% confidence The document is an Annual Secretarial Compliance Report filed under SEBI (LODR) Regulations, 2015, containing a Practicing Company Secretary’s certification of compliance with various listing and disclosure requirements. It is not a financial statement (Annual Report, Interim Report, or Earnings Release) nor an announcement of upcoming report publication. It is a regulatory compliance document submitted to the stock exchange, fitting the “Regulatory Filings” category.
2026-05-29 English
Newspaper Publication of the Audited Financial Results of the Company for the Quarter and Year ended 31st March, 2026.
Report Publication Announcement Classification · 85% confidence The document is a letter to the stock exchange notifying of the newspaper advertisement (i.e. publication) of the quarterly and year-end financial statements, with cuttings attached. It does not itself contain financial data or constitute an earnings release; rather it is an announcement that the report has been published. This matches the Report Publication Announcement (RPA) category.
2026-05-27 English
Re-appointment of Internal Auditor and Cost Auditor of the Company for the FY 2026-2027.
Interim / Quarterly Report Classification · 90% confidence The document is a SEBI LODR Reg.30/33 disclosure to BSE of the company’s audited financial results for the quarter and financial year ended March 31, 2026. It includes the full P&L, Statement of Assets & Liabilities and cash flows, not merely a notice or link. This aligns with a periodic interim/quarterly report containing substantive financial statements rather than a mere earnings highlight (ER) or notice (RPA). Therefore, it is classified as an Interim/Quarterly Report. FY 2026
2026-05-25 English
Revised Outcome.
Interim / Quarterly Report Classification · 85% confidence The document is a Board Meeting outcome under SEBI LODR Regulations including the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, complete with P&L, assets & liabilities, cash flows, and notes. This is not merely a brief earnings announcement (ER) but includes full financial statements. It is not a full Annual Report (10-K) or a mere publication notice, but a comprehensive periodical financial report for a quarter/year. Therefore, it fits the Interim/Quarterly Report category (IR). FY 2026
2026-05-25 English
Press Release titled Fredun Pharmaceuticals Announces 2:1 Bonus Issue, Signaling Strong Growth Confidence
Share Issue/Capital Change Classification · 85% confidence The document is a press release announcing a 2:1 bonus issue of equity shares by Fredun Pharmaceuticals. A bonus issue is a change in share capital structure (distribution of additional shares to existing shareholders), which falls under the Share Issue/Capital Change category. Therefore, the correct classification is SHA.
2026-05-25 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.